The European Commission has approved Pfizer’s Revatio (sildenafil) in an injectable solution for patients affected with rare and incurable pulmonary arterial hypertension (PAH) who cannot take oral medicine.

PAH affects an estimated 100,000 men and women worldwide and is characterised by continuous high blood pressure in the pulmonary arteries, leading to heart failure and premature death.

Belgium’s Erasme Hospital Pulmonary Vascular Diseases Unit professor of cardiology and director of pulmonary vascular diseases Jean-Luc Vachiery said that medical treatment can help delay damage caused by the disease.

“With the approval of the Revatio solution for injection, we have an option to bridge interruptions in the treatment of adult patients who may be temporarily unable to take this important therapy in tablet form,” Vachiery said.

Revatio is now the only phosphodiesterase 5 inhibitor with oral and IV formulations approved in the EU for the treatment of PAH.